Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review

Abstract

Examination of subcomponents of executive functioning is recommended to better characterize the nature of executive dysfunction in women treated with chemotherapy. Future studies should include executive functioning tasks of varying complexity, use of multiple tasks to increase reliability, and alternative indices to capture performance, such as within-person variability.

Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy

“…Another issue is study retention, i.e. the proportion and composition of cases having dropped out (11,17). Attrition may result in the selection of data and miss the most vulnerable cases; this phenomenon is more relevant in studies with long follow-up.…”

“…The adverse effects of adjuvant therapies on cognitive functioning including verbal memory (immediate and delayed recall), visuo-spatial memory, executive functioning, attention/concentration, psychomotor speed, verbal fluency, verbal articulation (language skills) may exert profound effects on quality of life (QOL) (6)(7)(8). Chemotherapy-related cognitive deterioration originally named as "chemobrain" is a wellknown phenomenon which includes various chemotherapyinduced deficits and impairments such as decline of verbal memory and psychomotor functioning (3,(9)(10)(11). Similar consequences of endocrine therapy (ET) have been less intensively investigated.…”

Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort

“…2018; 1-14. wileyonlinelibrary.com/journal/hed survivors of childhood cancers. [1][2][3][4][5][6][7][8][9][10] Interestingly, studies examining NCF in women with breast cancer indicate that a subset have deficits before receiving chemotherapy, 11,12 and similar pretreatment deficits have been reported in hematological patients before hematopoietic stem cell transplants. 13 Both self-reported and objective neurocognitive deficits have been reported but the concordance between them is limited, making it essential to assess both.…”

Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients

“…The cognitive impairments associated with chemotherapy have been observed up to 2 years after therapy in prospective longitudinal studies [99] and as long as 21 years after treatment in cross-sectional studies [100]. Deficits in both immediate and delayed memory recall, working memory, attention, and processing speed have been reported [101] but with a large intraindividual variability [102][103][104].…”